



WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas

Supplementary Materials



Supplementary Figure 1: (A) We used CCK-8 to determine NSCLC cell viability following treatment with 0, 0.625, 1.25, 2.5, 5, or 10 μM WP1130 alone for 24 h. *** $P < 0.0001$ vs. 0 μM WP1130. (B) CCK-8 was used to examine NSCLC cell viability following treatment with 0, 0.625, 1.25, 2.5, 5, or 10 μM WP1130 alone for 72 h. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.0001$ vs. 0 μM WP1130.



Supplementary Figure 2: (A) We detected the expression of p53 mRNA in xenograft tumors through RT-PCR (B) RT-qPCR showing p53 mRNA expression in NSCLC cells transfected with USP9X siRNA, a negative control siRNA or control. (C) Expression levels of p53 following treatment with or without WP1130 as determined by RT-qPCR. (D) Western Blot was used to determine the expression of MDM2 treatment with or without WP1130.